Trial
NCT03981744
A Study of Ustekinumab in Participants With Active Polymyositis and Dermatomyositis Who Have Not Adequately Responded to One or More Standard-of-care Treatments
Phase IIITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
Janssen Pharmaceutical K.K.
Collaborators
—
Condition
Polymyositis
Intervention
Ustekinumab 6 mg/kg
Why stopped
The study did not meet the primary endpoint.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-04-29